// App-Quantinova.ai

2325 : Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine

Researchers

Presenter

  • Carolina Fazio

Principal Investigators

  • Alessia Covre

  • Maria Lofiego

  • Pietro Taverna

  • Mohammad Azab

  • James N. Lowder

  • Sandra Coral

  • Michele Maio

Medical Centers

  • University Hospital of Siena, Siena, Italy

  • Astex Pharmaceuticals, Inc., Pleasanton, CA

  • Epigen Therapeutics, Pordenone, Italy.

Locations

  • United States

  • Italy

Companies

  • Astex Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Lung Cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Programmed cell death 1 ligand 2

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • guadecitabine

  • SGI-110

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved